A. Mathioudakis (Stockport, United Kingdom), M. Lommatzsch (Rostock, Germany)
Introduction
A. Mathioudakis (Stockport, United Kingdom), M. Lommatzsch (Rostock, Germany)
|  |
RCT Abstract - Airway smooth muscle mass to predict response to ICS in COPD patients receiving triple therapy (HISTORIC study): a randomized, placebo-controlled, double-blind, investigator-initiated trial
D. Stolz (Freiburg, Germany), E. Papakonstantinou (Basel, Switzerland), M. Pascarella (Basel, Switzerland), K. Jahn (Basel, Switzerland), A. Siebeneichler (Basel, Switzerland), A. Darie (Basel, Switzerland), M. Herrmann (Basel, Switzerland), W. Strobel (Basel, Switzerland), A. Salina (Basel, Switzerland), L. Grize (Basel, Switzerland), M. Tamm (Basel, Switzerland)
|   |
The effect of integrated palliative care on quality of life and acute healthcare use in patients with COPD – results of the COMPASSION study
J. Broese (Leiden, Netherlands), R. Van Der Kleij (Leiden, Netherlands), E. Verschuur (Amersfoort, Netherlands), E. Bronkhorst (Nijmegen, Netherlands), Y. Engels (Nijmegen, Netherlands), H. Kerstjens (Groningen, Netherlands), N. Chavannes (Leiden, Netherlands)
|  |
Pulmonary rehabilitation changes the oral microbiota of people with COPD
S. Melo-Dias (Aveiro, Portugal), M. Cabral (Aveiro, Portugal), A. Furtado (Aveiro, Portugal), S. Souto-Miranda (Aveiro, Portugal), J. Carvo (Aveiro, Portugal), A. Mendes (Aveiro, Portugal), C. Almeida (Aveiro, Portugal), A. Marques (Aveiro, Portugal), S. Ana (Aveiro, Portugal)
| |
Benefit of prompt initiation of single-inhaler triple therapy in COPD patients in England following an exacerbation
A. Ismaila (Collegeville, United States), R. Wood (Bollington, United Kingdom), A. Czira (Brentford, United Kingdom), V. Banks (Bollington, United Kingdom), L. Camidge (Bollington, United Kingdom), O. Massey (Bollington, United Kingdom), R. Sharma (Brentford, United Kingdom), C. Compton (Brentford, United Kingdom), K. Rothnie (Brentford, United Kingdom)
| |
Commencement of fixed dose ICS of varying particle size as a predictor of pneumonia in COPD patients
D. Price (Singapore, Singapore), W. Henley (Singapore, Singapore), V. Carter (Singapore, Singapore), D. Skinner (Singapore, Singapore), R. Vella (Singapore, Singapore), A. Papi (Ferrara, Italy), L. Fabbri (Ferrara, Italy), H. Kerstjens (Groningen, Germany), N. Roche (Paris, France), D. Singh (Manchester, United Kingdom), C. Vogelmeier (Marburg, Germany), E. Sen (Ankara, Turkey), J. Cançado (São Paulo, Brazil), M. Kots (Parma, Italy), E. Nudo (Parma, Italy), S. Barile (Parma, Italy), G. Georges (Parma, Italy), W. Henley (United Kingdom)
| |
Antimicrobial properties of Gallium Protoporphyrin in COPD
J. Baker (MANCHESTER, United Kingdom), A. Baba-Dikwa (MANCHESTER, United Kingdom), S. Lea (MANCHESTER, United Kingdom), D. Singh (MANCHESTER, United Kingdom)
| |
Machine learning-based individual treatment effect estimation of azithromycin on COPD exacerbations
K. Verstraete (Leuven, Belgium), I. Gyselinck (Leuven, Belgium), M. Staes (Leuven, Belgium), S. Lindberg (Minneapolis, United States), R. Albert (Denver, United States), J. Connett (Minneapolis, United States), M. De Vos (Leuven, Belgium), W. Janssens (Leuven, Belgium)
| |
Similar Programmed Death Ligand 1 expression profile in COPD and NSCLC structural and immune cells
R. Esposito (Caserta, Italy), D. Mirra (Caserta, Italy), G. Spaziano (Naples, Italy), E. Cione (Cosenza, Italy), L. Gallelli (Catanzaro, Italy), A. Capuozzo (Scafati, Italy), C. Santoriello (Naples, Italy), M. Polverino (Scafati, Italy), B. D'Agostino (Caserta, Italy), F. Polverino (Houston, United States)
| |
Effects of inhaled corticoids on chronic bronchial infection by Pseudomonas aeruginosa in COPD patients
N. Cerón Pisa (Palma, Spain), A. Iglesias (Palma, Spain), H. Shafiek (Alexandria, Egypt), E. Jordana-Lluch (Palma, Spain), M. Escobar-Salom (Palma, Spain), J. Verdú (Palma, Spain), C. López (Palma, Spain), A. Oliver (Palma, Spain), C. Juan (Palma, Spain), B. G Cosío (Palma, Spain)
| |
Randomized double blind placebo-controlled study to demonstrate that antibiotics are not needed in moderate acute exacerbations of COPD - Results from the ABACOPD study
G. Rohde (Frankfurt am Main, Germany), S. Häckl (Hannover, Germany), A. Koch (Hannover, Germany), M. Kolditz (Dresden, Germany), H. Timmermann (Hamburg, Germany), S. Andreas (Immenhausen, Germany), G. Barten (Hannover, Germany), T. Welte (Hannover, Germany), T. Abacopd Study Group (Hannover, Germany)
| |